Cargando…

Costs and healthcare utilisation of patients with chronic kidney disease in Spain

BACKGROUND: Data about the impact of chronic kidney disease (CKD) on health care costs in Spain are scarce This study was aimed to evaluate cumulative costs and healthcare utilisation in CKD in Spain. METHODS: Observational, retrospective, population-based study, which included adults who received c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escobar, Carlos, Palacios, Beatriz, Aranda, Unai, Capel, Margarita, Sicras, Antoni, Sicras, Aram, Hormigo, Antonio, Alcázar, Roberto, Manito, Nicolás, Botana, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167969/ https://www.ncbi.nlm.nih.gov/pubmed/34074269 http://dx.doi.org/10.1186/s12913-021-06566-2

Ejemplares similares

Costs and healthcare utilisation of patients with heart failure in Spain
por: Escobar, Carlos, et al.
Publicado: (2020)

Risk of outcomes in a Spanish population with chronic kidney disease
por: Alcázar, Roberto, et al.
Publicado: (2022)

The 2021 European Society of Cardiology Cardiovascular Disease Prevention Guidelines: adding albuminuria to the SCORE scale increases the prevalence of very high/high cardiovascular risk among patients with chronic kidney disease
por: Cebrian, Ana, et al.
Publicado: (2022)

Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain
por: Escobar-Cervantes, Carlos, et al.
Publicado: (2022)

Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2022)

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain
por: Rejas-Gutierrez, Javier, et al.
Publicado: (2021)

Impact on healthcare resource utilization of multiple sclerosis in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Healthcare use and costs associated with obesity in Badalona, Spain: a study protocol
por: Sicras-Mainar, Antonio, et al.
Publicado: (2012)

Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
por: Colet, Josep Comín, et al.
Publicado: (2023)

Adaptive capacity of the Adjusted Clinical Groups Case-Mix System to the cost of primary healthcare in Catalonia (Spain): a observational study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Disease Burden and Costs in Moderate-to-Severe Chronic Osteoarthritis Pain Refractory to Standard of Care: Ancillary Analysis of the OPIOIDS Real-World Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2021)

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain
por: Neches García, Victoria, et al.
Publicado: (2022)

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2020)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2019)

Treatment profiles and costs of patients with chronic pain in the population setting
por: Mainar, Antoni Sicras, et al.
Publicado: (2012)

Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study
por: Irimia, Pablo, et al.
Publicado: (2022)

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study
por: Barrios, Vivencio, et al.
Publicado: (2022)

Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
por: Prados-Torres, Alexandra, et al.
Publicado: (2009)

Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
por: Sanchez-Gistau, Vanessa, et al.
Publicado: (2023)

Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study
por: Soler-Cataluña, Juan José, et al.
Publicado: (2023)

Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
por: Molina, Jesús, et al.
Publicado: (2023)

Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain
por: Rodríguez-Quintosa, Jaime, et al.
Publicado: (2022)

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
por: Sicras-Mainar, A., et al.
Publicado: (2018)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
por: Cordero, Alberto, et al.
Publicado: (2023)

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity
por: Sicras‐Mainar, Antoni, et al.
Publicado: (2016)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Physicians’ and patients’ opinions on the use of generic drugs
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection
por: Sicras-Mainar, Antoni, et al.
Publicado: (2020)

Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2007)

Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fhr7og2mt163cpki96srjt6osg